Altamira Therapeutics Ltd. Secures Japanese Patent Allowance for Bentrio Nasal Spray

Altamira Therapeutics announced that its associate company, Altamira Medica, has received a notice of allowance from the Japan Patent Office covering Bentrio nasal spray.

The patent strengthens intellectual property protection in Japan — one of the world’s largest and highest-prevalence allergic rhinitis markets.

Product Overview: Drug-Free Nasal Protection

Bentrio is an over-the-counter, drug-free, preservative-free nasal spray approved or cleared in multiple countries for:

• Prophylaxis of allergic rhinitis
• Treatment support in allergic rhinitis
• In certain jurisdictions, protection against airborne viruses

Unlike antihistamines or corticosteroids, Bentrio works via a physical mechanism.

Triple Mode of Protection:

1. Formation of a protective gel barrier on nasal mucosa
2. Trapping of airborne allergens
3. Moisturization of the mucosal surface

This mechanical mode of action positions Bentrio as a medical device rather than a pharmaceutical.

Strategic Importance of Japan

Japan represents a high-value target market due to:

• Extremely high allergic rhinitis prevalence (~50% population estimates)
• Significant incidence of Japanese cedar pollinosis
• Established OTC consumer health infrastructure

Securing patent protection in Japan:

• Extends lifecycle protection
• Supports premium positioning
• Enhances partner negotiation leverage
• Protects against local generic device replication

Given the scale of seasonal pollen exposure in Japan, commercial opportunity is substantial.

Clinical Evidence: NASAR Study

The largest clinical trial, NASAR (n=100 seasonal allergic rhinitis patients), compared Bentrio to saline over two weeks.

Key findings:

• Statistically significant reduction in rTNSS (p = 0.013)
• Highly significant improvement in quality of life (p < 0.001)
• Fewer rescue medication uses
• Increased symptom-free days
• Safety profile comparable to saline

While modest in scale, these results support differentiation versus simple saline sprays.

Competitive Positioning

Bentrio competes in a crowded allergic rhinitis landscape that includes:

• Oral antihistamines
• Intranasal corticosteroids
• Leukotriene inhibitors
• Allergen immunotherapy

Its differentiation lies in:

• Drug-free positioning
• Favorable safety profile
• Suitability for pediatric and polypharmacy populations
• Complementary use alongside pharmacologic treatments

In markets with strong consumer health segments, mechanical barrier devices can capture meaningful niche share.

Broader Corporate Context

Altamira Therapeutics’ core strategic focus is its xPhore peptide-based nanoparticle platform for nucleic acid delivery.

This platform supports modalities including:

• siRNA
• mRNA
• circRNA
• DNA

The Bentrio business provides:

• Diversified revenue potential
• Regulatory and commercialization expertise
• IP portfolio strengthening

However, long-term valuation likely centers on its nucleic acid delivery partnerships rather than OTC nasal products.

Strategic Takeaway

The Japanese patent allowance for Bentrio:

• Secures IP protection in a high-prevalence allergy market
• Reinforces commercialization potential in Asia
• Enhances asset defensibility

While not a breakthrough pharmaceutical innovation, Bentrio represents a differentiated consumer-health device with clinically supported efficacy and strong positioning in allergy-heavy markets.

For Altamira, the milestone strengthens near-term commercial optionality while its nucleic acid delivery platform remains the longer-term strategic growth engine.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!